Perturbação de Hiperatividade/Défice de Atenção no Adulto: Um Posicionamento de Peritos Portugueses sobre Diagnóstico e Tratamento
DOI:
https://doi.org/10.20344/amp.22149Palavras-chave:
Adult, Attention Deficit Disorder with Hyperactivity/diagnosis, Attention Deficit Disorder with Hyperactivity/therapy, PortugalResumo
A perturbação de hiperatividade e défice de atenção (PHDA) é uma perturbação do neurodesenvolvimento que frequentemente persiste na vida adulta, afetando aproximadamente 1,5% - 3% da população adulta em Portugal. A PHDA não tratada em adultos está ligada a um risco aumentado de abuso de substâncias, criminalidade, baixo desempenho académico e profissional. Menos de 20% dos adultos com PHDA são diagnosticados e tratados adequadamente, devido a sintomas sobrepostos com outras perturbações mentais, à existência de comorbilidades, ou ao desconhecimento e preconceitos sobre esta perturbação. Este documento de posicionamento resulta da realização de reuniões de peritos envolvendo seis psiquiatras portugueses experientes na gestão da PHDA em adultos. Visa orientar estratégias de diagnóstico e tratamento, bem como abordar as principais barreiras e limitações no acompanhamento destes doentes no contexto português, ao nível do diagnóstico e tratamento. Este documento pretende ainda esclarecer e desmistificar preconceitos, aumentar a consciencialização médica e promover a discussão para a elaboração de diretrizes para melhorar o diagnóstico, tratamento e qualidade de vida dos adultos com PHDA em Portugal.
Downloads
Referências
REFERÊNCIAS
Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17:302. DOI: https://doi.org/10.1186/s12888-017-1463-3
Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The descriptive epidemiology of dsm-iv adult adhd in the world health organization world mental health surveys. Atten Defic Hyperact Disord. 2017;9:47-65.
Almeida J, Xavier M, Cardoso G, Gonçalves Pereira M, Gusmão R, Barahona Correa B, et al. Estudo epidemiológico nacional de saúde mental. 1.º Relatório. Lisboa: Faculdade de Ciências Médicas da Universidade Nova de Lisboa; 2013.
Kranz TM, Grimm O. Update on genetics of attention deficit/hyperactivity disorder: current status 2023. Curr Opin Psychiatry. 2023;36:257-62. DOI: https://doi.org/10.1097/YCO.0000000000000852
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-65. DOI: https://doi.org/10.1017/S003329170500471X
Caye A, Rocha TB, Anselmi L, Murray J, Menezes AM, Barros FC, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry. 2016;73:705-12. DOI: https://doi.org/10.1001/jamapsychiatry.2016.0383
Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, et al. Is adult adhd a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015;172:967-77. DOI: https://doi.org/10.1176/appi.ajp.2015.14101266
Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiatry. 2016;73:713-20. DOI: https://doi.org/10.1001/jamapsychiatry.2016.0465
Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from adhd in the multimodal treatment study of adhd. Am J Psychiatry. 2022;179:142-51. DOI: https://doi.org/10.1176/appi.ajp.2021.21010032
Bohmwald K, Andrade CA, Galvez NM, Mora VP, Munoz JT, Kalergis AM. The causes and long-term consequences of viral encephalitis. Review. Front Cell Neurosci. 2021;15:755875. DOI: https://doi.org/10.3389/fncel.2021.755875
Adeyemo BO, Biederman J, Zafonte R, Kagan E, Spencer TJ, Uchida M, et al. Mild traumatic brain injury and adhd: a systematic review of the literature and meta-analysis. J Atten Disord. 2014;18:576-84. DOI: https://doi.org/10.1177/1087054714543371
Dobrosavljevic M, Larsson H, Cortese S. The diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults. Expert Rev Neurother. 2023;23:883-93. DOI: https://doi.org/10.1080/14737175.2023.2250913
Beauchaine TP, Ben-David I, Bos M. ADHD, financial distress, and suicide in adulthood: a population study. Sci Adv. 2020;6:eaba1551. DOI: https://doi.org/10.1126/sciadv.aba1551
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020. DOI: https://doi.org/10.1038/nrdp.2015.20
Chang Z, Lichtenstein P, D’Onofrio BM, Sjolander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry.
;71:319-25.4
Pozzi M, Bertella S, Gatti E, Peeters G, Carnovale C, Zambrano S, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs. 2020;25:395-407. DOI: https://doi.org/10.1080/14728214.2020.1820481
Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr. 2008;13:977-84. DOI: https://doi.org/10.1017/S1092852900014036
Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care Companion CNS Disord. 2014;16:PCC.13r01600. DOI: https://doi.org/10.4088/PCC.13r01600
McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr. 2012;12:78. DOI: https://doi.org/10.1186/1471-2431-12-78
Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-8. DOI: https://doi.org/10.1176/appi.ajp.157.5.816
Costa Alves J, Morais S, Ferreira de Macedo A. Consulta de psiquiatria do neurodesenvolvimento: uma analise a nivel nacional. Acta Med Port. 2023;36:802-10. DOI: https://doi.org/10.20344/amp.19652
National Institute for Health and Care Excellence. Guidelines. Attention deficit hyperactivity disorder: diagnosis and management. 2019. [consultado 2024 jul 09]. Disponível em: https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorderdiagnosis-and-management-pdf-1837699732933.
Royal College of Psychiatrists. College Report CR235 - ADHD in adults: Good practice guidance. 2023. [consultado 2024 jul 09]. Disponível em: https://www.rcpsych.ac.uk/docs/default-source/improving-care/
better-mh-policy/college-reports/cr235-adhd-in-adults---good-practiceguidance.pdf?sfvrsn=7c8cc8e4_12.
Australasian ADHD Professionals Association (AADPA). Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder (ADHD). Australia: AADPA; 2022.
Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, et al. Updated european consensus statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14-34. DOI: https://doi.org/10.1016/j.eurpsy.2018.11.001
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5™). Washington, DC: American Psychiatric Publishing; 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596
Ramos-Quiroga JA, Nasillo V, Richarte V, Corrales M, Palma F, Ibanez P, et al. Criteria and concurrent validity of diva 2.0: a semi-structured diagnostic interview for adult adhd. J Atten Disord. 2019;23:1126-35. DOI: https://doi.org/10.1177/1087054716646451
National Comorbidity Survey (NCS). Adult ADHD Self-Report Scales: ASRS. [consultado 2024 out 28]. Disponível em: https://www.hcp.med.harvard.edu/ncs/asrs.php.
Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:179-203. DOI: https://doi.org/10.1177/0269881113519509
Sadek J. Malingering and stimulant medications abuse, misuse and diversion. Brain Sci. 2022;12:1004. DOI: https://doi.org/10.3390/brainsci12081004
Patel GR. Feigning adhd: a necessary exploration of an uncomfortable topic. Journal of the New Zealand College of Clinical Psychologists. 2023;33:61-71.
Fuermaier AB, Fricke JA, de Vries SM, Tucha L, Tucha O. Neuropsychological assessment of adults with ADHD: a delphi consensus study. Appl Neuropsychol Adult. 2019;26:340-54. DOI: https://doi.org/10.1080/23279095.2018.1429441
Sobanski E, Bruggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (adhd). Eur Arch Psychiatry Clin Neurosci. 2007;257:371-7. DOI: https://doi.org/10.1007/s00406-007-0712-8
Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: a study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry. 2006;60:38-43. DOI: https://doi.org/10.1080/08039480500520665
Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The descriptive epidemiology of dsm-iv adult adhd in the world health organization world mental health surveys. Atten Defic Hyperact Disord. 2017;9:47-65. DOI: https://doi.org/10.1007/s12402-016-0208-3
Young S, Adamo N, Asgeirsdottir BB, Branney P, Beckett M, Colley W, et al. Females with ADHD: an expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC Psychiatry. 2020;20:404. DOI: https://doi.org/10.1186/s12888-020-02707-9
Landau Z, Pinhas-Hamiel O. Attention deficit/hyperactivity, the metabolic syndrome, and type 2 diabetes. Curr Diab Rep. 2019;19:46. DOI: https://doi.org/10.1007/s11892-019-1174-x
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727-38. DOI: https://doi.org/10.1016/S2215-0366(18)30269-4
Stuhec M, Lukic P, Locatelli I. Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis. Ann Pharmacother. 2019;53:121-33. DOI: https://doi.org/10.1177/1060028018795703
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The world federation of adhd international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. DOI: https://doi.org/10.1016/j.neubiorev.2021.01.022
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28:1059-88. DOI: https://doi.org/10.1016/j.euroneuro.2018.08.001
Li L, Zhu N, Zhang L, Kuja-Halkola R, D’Onofrio BM, Brikell I, et al. ADHD pharmacotherapy and mortality in individuals with adhd. JAMA. 2024;331:850-60. DOI: https://doi.org/10.1001/jama.2024.0851
Direção-Geral da Saúde. Norma n.º 002/2019: abordagem diagnóstica e intervenção na perturbação do espectro do autismo em idade pediátrica e no adulto. Lisboa: DGS; 2019.
Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. London: John Wiley & Sons; 2021. DOI: https://doi.org/10.1002/9781119870203
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2025 Acta Médica Portuguesa
Este trabalho encontra-se publicado com a Creative Commons Atribuição-NãoComercial 4.0.
Todos os artigos publicados na AMP são de acesso aberto e cumprem os requisitos das agências de financiamento ou instituições académicas. Relativamente à utilização por terceiros a AMP rege-se pelos termos da licença Creative Commons ‘Atribuição – Uso Não-Comercial – (CC-BY-NC)’.
É da responsabilidade do autor obter permissão para reproduzir figuras, tabelas, etc., de outras publicações. Após a aceitação de um artigo, os autores serão convidados a preencher uma “Declaração de Responsabilidade Autoral e Partilha de Direitos de Autor “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) e a “Declaração de Potenciais Conflitos de Interesse” (http://www.icmje.org/conflicts-of-interest) do ICMJE. Será enviado um e-mail ao autor correspondente, confirmando a receção do manuscrito.
Após a publicação, os autores ficam autorizados a disponibilizar os seus artigos em repositórios das suas instituições de origem, desde que mencionem sempre onde foram publicados e de acordo com a licença Creative Commons
